Teodora Staeva Archives - Lupus Research

Tag: Teodora Staeva

CAR T Cell Therapy Induces Lupus Remission in Small Study

September 21, 2022 Results of a small study published in the prestigious journal Nature Medicine, suggest that a type of immune cell therapy called chimeric antigen receptor (CAR) T cell therapy could become a highly effective therapy for SLE patients who do not respond to current lupus treatments. CD19 CAR T cells are T cells that […] Read More

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] Read More

Pivotal LRA-Funded Research Shared at Annual Rheumatology Meeting

November 15, 2021 The Lupus Research Alliance (LRA) supports research into causes and mechanisms of lupus, and identification of targets supporting the development of new therapies or cures for lupus patients. At this year’s meeting of the American College of Rheumatology (ACR), 17 LRA-funded researchers presented their work to share discoveries with the thousands of […] Read More

LRA’s Virtual Annual Conference Brings Together Top Lupus Researchers for Dynamic Scientific Exchange

October 28, 2021 Two-day meeting focuses on sharing latest news and generating new scientific ideas The Lupus Research Alliance (LRA) held our annual scientific conference, the Forum for Discovery, online for a second year given the continued concerns during the COVID-19 pandemic. The virtual capability allowed more than 150 funded investigators, scientific advisors, and partners […] Read More

Two LRA-Funded Studies Offer New Insight into Why Lupus is More Common in Women

October 14, 2021 When it comes to the likelihood of developing an autoimmune disease such as lupus, there is a clear difference between sexes, with 9 women diagnosed for every one man. Two recent studies, both funded by the Lupus Research Alliance (LRA), offer insight into what may be driving this difference. Part of the […] Read More

Lupus Research Alliance Sets Bold New Strategic Plan for Research to Accelerate Innovative Research and Treatment Breakthroughs

Updated July 15, 2021 The Lupus Research Alliance (LRA) today announced a bold Strategic Plan for Research (Strategic Plan) that identifies core issues and sets new priorities to transform lupus research, accelerate breakthrough treatments and ultimately, find a cure through the power of precision medicine. The Strategic Plan is informed by years of funded research […] Read More

Lupus Research Alliance Announces Seven Recipients of the 2020 Lupus Innovation Award

NEW YORK, NY, November 9, 2020. The Lupus Research Alliance proudly announced today the 2020 Lupus Innovation Award recipients. These seven projects represent a wide breadth of scientific exploration in lupus, probing the development and progression of lupus while pointing to potential treatment approaches. The Lupus Innovation Award offers up to $150,000/year total costs for […] Read More

LRA’s 2020 LMTA Grantees Focus on Finding Targets for New Lupus Drug Development

December 3, 2020 NEW YORK, NY. December 3 – The Lupus Research Alliance is proud to announce the 2020 recipients of its Lupus Mechanisms and Targets Award (LMTA). The highly competitive grant gives researchers up to $200,000 a year for up to three years. As indicated by the title of the award, the 2020 awardees […] Read More

COVID-19 Caused Hydroxychloroquine Issues for Third of Lupus Patients, New LRA Survey Finds

NEW YORK, NY, May 28. More than one third of people with lupus experienced significant issues filling their hydroxychloroquine (Plaquenil) prescriptions during the COVID-19 pandemic, according to results of a new survey conducted by the Lupus Research Alliance (LRA). Hydroxychloroquine shortages in March and April coincided with early data broadly reported in the media suggesting […] Read More

Lupus and COVID-19: What You Need to Know – LIVE WEBCAST May 21 at 6 PM ET

Since the arrival of the novel coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine – have been thrust into the public spotlight despite the mounting scientific evidence that drug does not appear to improve clinical outcomes in patients with COVID-19. What has been talked about less is what the impact […] Read More